Compare Microchip Technology Inc. (MCHP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Pfizer Inc — how do they compare? Microchip Technology Inc. trades at $79.86 (market cap $43.99B), while Pfizer Inc trades at $26.35 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 3.4× Microchip Technology Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| MCHP | PFE | |
|---|---|---|
Market Cap | $43.99B | $151.73B |
Sector | Technology | Health |
52-Week High | $102.97 | $28.56 |
52-Week Low | $49.02 | $23.60 |
Enterprise Value | $49.12B | $203.22B |
Dividend Yield | 2.25% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $80.11, down 1.57% over the past day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust data center revenue growth, including a 98% surge last quarter, highlight operational momentum. The company maintains solid cash flow and a healthy balance sheet, though elevated valuation ratios like a P/E of 119.15 warrant caution.
Outlook remains positive driven by AI and data center demand, with a consensus price target of $104 implying significant upside. Risks include high debt levels and sensitivity to semiconductor cycles. Institutional sentiment is strong with no sell ratings among 44 analysts, supporting a favorable investment case amid broader tech recovery trends.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
